145240-76-2

Upstream product

• 134038-85-0 (S)-2-((2S,4R)-5-Benzyloxycarbonylamino-2-tert-butoxycarbonylamino-4-hydroxy-pentanoylamino)-3-{4,4'-bis-benzyloxy-3'-[(S)-2-benzyloxycarbonylamino-2-(2-trimethylsilanyl-ethoxycarbonyl)-ethyl]-biphenyl-3-yl}-propionic acid benzyl ester 
• 1761-62-2 5-iodosalicyclaldehyde 
• 121124-94-5 2-benzyloxy-5-bromobenzaldehyde 
• 134038-81-6 (Z)-3-(4,4'-Bis-benzyloxy-3'-[1,3]dioxan-2-yl-biphenyl-3-yl)-2-tert-butoxycarbonylamino-acrylic acid methyl ester 
• 135582-94-4 (R)-3-benzyloxycarbonyl-5-<(S)-2-(tert-butoxycarbonylamino)-2-(methoxycarbonyl)ethyl>-2,2-dimethyl-1,3-oxazolidine 
• 135638-41-4 (R)-3-benzyloxycarbonyl-5-<(Z)-2-(tert-butoxycarbonylamino)-2-(methoxycarbonyl)vinyl>-2,2-dimethyl-1,3-oxazolidine 
• 134038-76-9 (R)-3-Benzyloxycarbonyl-5-<(S)-N-tert-butoxycarbonylalanin-3-yl>-2,2-dimethyl-1,3-oxazolidine 
• 135582-86-4 (S)-3-benzyloxycarbonyl-2,2-dimethyl-5-o-nitrobenzoyloxymethyl-1,3-oxazolidine 
• 134038-72-5 (S)-3-benzyloxycarbonylamino-2-hydroxy-1-(o-nitrobenzoyloxy)propane 
• 134038-71-4 (S)-4-benzyloxycarbonylaminomethyl-2,2-dimethyl-1,3-dioxolane 
• 134038-73-6 benzyl (S)-5-hydroxymethyl-2,2-dimethyl-1,3-oxazolidine-3-carboxylate 
• 134038-74-7 benzyl (S)-5-formyl-2,2-dimethyl-1,3-oxazolidine-3-carboxylate 
• 135582-93-3 (S)-3-[N-(benzyloxycarbonyl)amino]-1,2-propanediol 
• 1761-61-1 5-bromosalicyclaldehyde 

Downstream Products

• 134038-87-2 benzyl 5,17-bisbenzyloxy-14(S)-benzyloxycarbonylamino-11(S)-(3-benzyloxycarbonylamino-2(R)-hydroxypropyl)-10,13-dioxo-9,12-diazatricyclo[14.3.1.12,6]-henicosa-1(19),2,4,6(21),16(20),17-hexaene-8(S)-carboxylate 
• 100217-74-1 biphenomycin B 
• 134038-86-1 benzyl 2(S)-(5-benzyloxycarbonylamino-2(S)-tert-butoxycarbonylamino-4(R)-hydroxypentanoylamino)-3-[4,4'-bisbenzyloxy-3'-(2(S)-benzyloxycarbonylamino-2-pentafluorophenyloxycarbonylethyl)biphenyl-3-yl]propionate 

Relevant academic research and scientific papers

Antibacterial amide macrocycles

The invention relates to antibacterial amide macrocycles, to methods for the production thereof, and to the use of the same for producing pharmaceuticals for the treatment and/or prophylaxis of illness, especially bacterial infections.

Total synthesis of the biphenomycins; III. Synthesis of biphenomycin B

The total synthesis of the cyclopeptide biphenomycin B (1b), a compound exhibiting a potent antibacterial activity against Gram-positive bacteria, is described. The non-proteinogenic amino acid (S,S)-diisotyrosine (2) was prepared by enantioselective hydrogenation of the corresponding didehydroamino acids. The 15-membered ansa ring was obtained in 85% yield within 5 minutes by ring closure of the appropriate linear pentafluorophenyl ester in the two phase system chloroform-aqueous sodium hydrogen carbonate without dilution.

The Synthesis of Biphenomycin B

Biphenomycin B, a highly potent antibiotic against Gram-negative, β-lactam-resistant bacteria, which was previously isolated from culture filtrates of Streptomyces griseorubiginosus No. 43708, has now been synthesized.